MedTrace Logo

Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis

NCT02201524 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2016-10-05

Study results available
· View outcomes & findings →

Summary

Study B7451005 is a Phase 2 study which will assess the efficacy and safety of PF-04965842 in patients with moderate to severe psoriasis. The study will include three PF-04965842 groups (200 mg daily, 400 mg daily and 200 mg twice daily) and a placebo group. The treatment period will be 4 weeks in duration and will be followed up by a 4 week follow up period.

Conditions

Interventions

DRUG

PF-04965842

Subjects will receive 200 mg PF 04965842 twice daily for 4 weeks

DRUG

PF-04965842

Subjects will receive 400 mg PF 04965842 daily for 4 weeks

DRUG

PF-04965842

Subjects will receive 200 mg PF 04965842 daily for 4 weeks

OTHER

Placebo

Subjects will receive placebo for 4 weeks

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02201524 on ClinicalTrials.gov